Advanced Filters
noise

Biejing, China Clinical Trials

A listing of Biejing, China clinical trials actively recruiting patients volunteers.

Found 2,216 clinical trials
H Hanqi Wang

RCT of Tocilizumab for Anti-MDA5+DM

The goal of this clinical trial is to learn if tocilizumab works to treat anti-MDA5+ dermatomyositis (anti-MDA5+DM) in adults. It will also learn about the safety of tocilizumab. The main questions it aims to answer are: Does tocilizumab improve patients' clinical symptoms? Does tocilizumab improve patients' respiratory failure? What medical …

18 - 65 years of age All Phase N/A

A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

This is an open-label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GEN-725 in combination with Dositinib in participants with locally advanced or metastatic EGFR-mutant non-small cell lung cancer.

18 - 75 years of age All Phase 1/2
J Jianzhong Zhang

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

18 - 75 years of age All Phase 2
Y Yongjun Wang

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND

The benefit-risk profile of thrombolysis for acute ischemic strokes beyond 24 hours has never been investigated. We initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to assess the safety and efficacy of tenecteplase (0.25mg/kg, max 25mg) versus standard medical treatment in acute ischemic stroke due to large …

18 years of age All Phase 3
Y Yajing Zhang

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to chronic inflammation and damage to organs such as the kidneys, lungs, muscles, nerves, or blood cells. Although many treatments are available, some patients do not respond adequately or experience repeated disease flares despite long-term therapy. …

18 - 70 years of age All Phase 1
J Jun Zhao, Postdoctor

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

This is a multicenter, randomized, open-label, phase III clinical study, to evaluate the efficacy and safety of IN10018 in combination with D-1553 as compared to anti-PD-1 monoclonal antibody (mAb) in combination with platinum and pemetrexed as the first-line treatment for the locally advanced or metastatic KRASG12C mutation-positive non-squamous non-small cell …

18 - 80 years of age All Phase 3
B BeiJing Cancer Hospital EC

Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma

This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma, aiming to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of JMT108 Injection in this population. The study consists of Phase I and Phase II (including Phase IIa and Phase IIb), …

18 years of age All Phase 1/2
K Kai Guan Principal Investigator

A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65

A research study of house dust mite (HDM) SLIT-tablet for the treatment of HDM allergy in Chinese participants aged 12-65.

12 - 65 years of age All Phase 3
J Jianzhong Zhang

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.

18 years of age All Phase 2
N Na Kuang

An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma

To observe the efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory or relapsed aggressive B-cell lymphoma

18 years of age All Phase 0

Simplify language using AI